These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26608138)

  • 41. Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma.
    Almokadem S
    Curr Mol Pharmacol; 2016; 9(3):226-230. PubMed ID: 26177644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma.
    Fang J; Li X; Ma D; Liu X; Chen Y; Wang Y; Lui VWY; Xia J; Cheng B; Wang Z
    BMC Cancer; 2017 May; 17(1):375. PubMed ID: 28549420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy in patients with oral malignant disease.
    Perlin E
    Otolaryngol Clin North Am; 1979 Feb; 12(1):195-9. PubMed ID: 440739
    [No Abstract]   [Full Text] [Related]  

  • 45. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck.
    Boscia R; Chen K; Johnson JT; Whiteside TL
    Ann Otol Rhinol Laryngol; 1988; 97(4 Pt 1):414-21. PubMed ID: 3261562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunopharmacology of head and neck cancer: an update.
    Hadden JW
    Int J Immunopharmacol; 1997; 19(11-12):629-44. PubMed ID: 9669203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials.
    Browder JP; Chretien PB
    Semin Oncol; 1977 Dec; 4(4):431-9. PubMed ID: 339354
    [No Abstract]   [Full Text] [Related]  

  • 48. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer.
    Tabachnyk M; Distel LV; Büttner M; Grabenbauer GG; Nkenke E; Fietkau R; Lubgan D
    Oral Oncol; 2012 Jul; 48(7):594-601. PubMed ID: 22356894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Treatment Options in Head and Neck Cancer.
    Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
    Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
    Nguyen N; Bellile E; Thomas D; McHugh J; Rozek L; Virani S; Peterson L; Carey TE; Walline H; Moyer J; Spector M; Perim D; Prince M; McLean S; Bradford CR; Taylor JM; Wolf GT;
    Head Neck; 2016 Jul; 38(7):1074-84. PubMed ID: 26879675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of monoclonal antibodies with specificity to oral squamous cell carcinoma.
    Fantozzi RD
    Laryngoscope; 1991 Oct; 101(10):1076-80. PubMed ID: 1921634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma.
    Atanackovic D; Blum I; Cao Y; Wenzel S; Bartels K; Faltz C; Hossfeld DK; Hegewisch-Becker S; Bokemeyer C; Leuwer R
    Cancer Biol Ther; 2006 Sep; 5(9):1218-25. PubMed ID: 16929165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current treatment of head and neck squamous cell cancer.
    Belcher R; Hayes K; Fedewa S; Chen AY
    J Surg Oncol; 2014 Oct; 110(5):551-74. PubMed ID: 25053506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?
    Ferris RL
    ORL J Otorhinolaryngol Relat Spec; 2004; 66(6):332-40. PubMed ID: 15668533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies.
    Lee SC; López-Albaitero A; Ferris RL
    Curr Oncol Rep; 2009 Mar; 11(2):156-62. PubMed ID: 19216848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions.
    Kiremidjian-Schumacher L; Roy M
    Biofactors; 2001; 14(1-4):161-8. PubMed ID: 11568453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Organ specificity of carcinoma originating from stratified epithelium and its treatment (5). 2. Treatment of head and neck tumors].
    Takeda C
    Gan No Rinsho; 1969 Mar; 15(3):276-7. PubMed ID: 5816297
    [No Abstract]   [Full Text] [Related]  

  • 60. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.